B. Riley Securities Downgrades Intercept Pharma to Neutral, Raises Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has downgraded Intercept Pharma from Buy to Neutral, while raising the price target from $15 to $19. The downgrade was announced by analyst Mayank Mamtani.

September 27, 2023 | 4:18 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Intercept Pharma has been downgraded to Neutral from Buy by B. Riley Securities, but the price target has been raised from $15 to $19.
The downgrade from Buy to Neutral suggests that B. Riley Securities sees less upside potential in Intercept Pharma's stock. However, the increase in price target from $15 to $19 indicates that they still see some potential for growth. This mixed signal could lead to uncertainty among investors, potentially leading to short-term price volatility.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100